BioCommerce Week s Index to the Diversified Molecular Biology Tools Companies | GenomeWeb

 

BioCommerce Week’s Index to the Diversified Molecular Biology Tools Companies

On a week when Merck withdrew its anti-inflammatory medicine Vioxx from the market, the BioCommerce Week Index of Diversified Molecular Biology Tools Companies recovered from last week’s 3-percent fall, registering a 2-percent gain for the weekly period ending Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.